portion of patients with small volume metastatic NSGCT are likely to be cured with chemotherapy alone. It is important to recognise this group and to minimise the trauma and morbidity of their treatment. Patients with more advanced presentations have gained from improvements in chemotherapy (Williams et al., 1987; Peckham et al., 1988) and from a greater understanding of the role of surgery for masses remaining after chemotherapy (Hendry et al., 1987; Donohue et al., 1982) , but there remains some 10-20% of patients with metastatic NSGCT who still die of their malignant disease and in this group the current challenge is to increase the efficacy of chemotherapy. This field also has broader relevance to other cancers, since the sensitivity of germ cell tumours to combination chemotherapy makes them an important testing ground of determinants of chemotherapy response such as dose, dose intensity and alternating regimens.
There is broad agreement between major centres that the factors determining prognosis in patients with metastatic germ cell tumours are volume and extent of metastatic disease, often described by the Royal Marsden Hospital stages which are given by Hitchins et al. (1989) and also by the serum concentration of tumour markers (alphafetoprotein AFP, human chorionic gonadotrophin HCG, lactate dehydrogenase LDH). The Medical Research Council Testicular Tumour Working Party (MRCTTWP) analysed prognostic factors in 458 patients treated with chemotherapy between 1976 and 1982 (MRC, 1985 . Disease extent and serum marker concentrations were found to be equally important prognostic variables. The subgroup of 180 patients with both small volume disease (RMH stages IM, IIA, IIB,  IIIA, IIIB, IVALI, IVAL2, IVBLI, IVBL2) (MRC, 1985; Einhorn, 1986) .
A number of groups have produced prognostic classifications and in general these are based on the distribution and volume of metastatic disease, e.g. The Indiana
University (Einhorn et al., 1985) and the MD Anderson Hospital (Logothetis et al., 1986) . The Sloan Kettering (MSKCC) have derived a prognostic index which enables calculation of the probability of complete remission based on actual values of LDH, HCG and the number of metastatic sites (Bosl et al., 1983) . The EORTC similarly defined four prognostic groups following a multivariate analysis of prognostic factors, the risk groups being defined by trophoblastic histology, concentration of AFP, and the size and number of lung metastases (MRC, 1985; Einhorn, 1986) . New important prognostic factors may be identified with increasing knowledge of teratoma tumour biology such as identification of different subtypes of teratoma stem cells (Pera et al., 1988) , characterisation of oncogene expression (Watson et al., 1986) , and measurements of tumour proliferation (Sledge et al., 1988; Price et al., 1988 Williams et al. (1987) patients with advanced disease on the Indiana University staging system faired better with BEP (survival probability at 2 years 76% versus 48% with PVB). Other approaches tested in prospective randomised studies have been dose escalation, especially of cisplatin and the use of alternating regimens. Following demonstration in germ cell tumours of dose response for cisplatin (Samson et al., 1984) and the mitigation of cisplatin renal toxicity by hydration with hypertonic saline (Ozols et al., 1984 ), this drug was tested at 40 mg m-2 x 5, double the usual dose. Severe toxicity has been demonstrated (Dougaard & Rorth, 1986) . At the NCI 'double dose' cisplatin was combined with etoposide, vinblastine and bleomycin (PVeBV) and the regimen has been compared with PVB in a prospective randomised trial in 'poor risk' patients (Ozols et al., 1988 ). Only 52 patients were randomised and median follow-up at the time of reporting was 4 years. The complete remission rate was higher with PVeBV (88% vs. 67%, P=0.14) and relapse was less common (17% vs. 41%, P=0.2). The actuarial 5-year survival was 78% for PVeBV versus 48% for PVB (P=0.06) and also disease free survival was significantly higher. Ninety-one per cent of patients treated with PVeBV had nadir total white blood-counts <1,0001-1 and 88% had neutropenic sepsis. Furthermore ototoxicity was severe and 12 patients required hearing aids following treatment.
Unfortunately, since standard dose BEP has been shown to be superior to PVB in advanced disease (vide supra) it is not clear that the survival benefits in the NCI study derived from the increased dose of cisplatin rather than from the inclusion of etoposide as an additional drug in the high dose arm.
In single-arm studies dose escalation is being investigated in conjunction with autologous bone-marrow transplantation (Nichols et al., 1988; Mulder et al., 1988; Ahlgren et al., 1988 (Newlands et al., 1986) . Volume of metastatic disease did not appear to be adverse with this schedule, however, survival in the 41 patients with serum HCG >50,000iUl-1 or AFP>500kUl -1 was 64% compared to 90% in 40 patients with lower marker concentrations. This regimen has been investigated independently by Cullen et al. (1988) who also found it to be highly effective in adverse subgroups. In their study of 60 patients treated between 1979 and 1987 there were 4 early deaths, 5 failures of remission induction and 4 relapses from remission. Four of 6 patients with liver metastases and 3 of 4 with brain metastases were free from progression at the time of reporting. Nevertheless in this series patients identified as poor risk on the MRC classification (MRC (1985) , very large volume plus high markers) had a 54% survival rate and this is comparable with standard regimens. Logothetis et al. (1985) report excellent results alternating CISCA2 (adriamycin, cyclophosphamide, cisplatin), with VBiv (vinblastine, bleomycin) with complete remission in 44 of 48 patients, though myelosuppressive complications were common with infections occurring after 45% of chemotherapy courses. On the other hand the MSKCC study of alternating EP/VAB-6 (Bosl et al., 1987) did not suggest that this approach was superior to standard VAB-6 and the EORTC randomised trial showed alternating BEP and PVB to be no better than BEP (Stoter et al., 1986) . At present treatment intensification and alternation of drug regimens have not been proved to improve survival in adverse presentations of germ cell tumour, but, these approaches do appear promising and merit evaluation in prospective randomised trials.
In patients with less extensive metastatic NSGCT the prognosis on standard chemotherapy is excellent (MRC, 1985; Williams et al., 1987; Peckham et al., 1988) and toxicity is an important issue in the choice of treatment. The major life threatening complications of drug regimens employed for germ cell tumours include myelosuppression and bleomycin-induced pneumonitis. Some patients suffering severe nausea and vomiting, abdominal cramps or dermatitis find it difficult to continue with chemotherapy. Some side effects are chronic and the full impact on the health of the patient may not yet be manifest. These include renal damage and ototoxicity due to cisplatin (Daugaard et al., 1988; Hamilton et al., 1989 ) and Reynaud's phenomenon due to bleomycin . Approaches to a reduction of chemotherapy toxicity include reduction of drug dosage, reduction of the number of drugs, the use of less toxic drugs or drug analogues, and the reduction of the total number of chemotherapy courses. A prospective randomised trial from Indiana University compared PVB containing vinblastine at 0.4mg kg-1 with the dose of 0.3mg kg-1 and suggested that therapeutic results were equivalent with considerably less toxicity with the lower dose (Einhorn & Williams, 1980) . However, this study was very small with only 26 and 27 patients in each arm and failure analysis would suggest that dosage of cisplatin (Samson et al., 1984) and of etoposide (Brada et al., 1987 ) may be of critical importance for antitumour effect. Total drug dosage can also be reduced by avoiding maintenance chemotherapy (Einhorn et al., 1981) or by reducing the total number of induction chemotherapy courses. A preliminary analysis of 184 good prognosis patients treated with either three or four courses of BEP indicates no difference in efficacy (Einhorn et al., 1988) .
A number of recent trials have suggested that bleomycin may be an unnecessary component of the chemotherapy of good prognosis patients. The EORTC study contained 180 good risk patients with lymph node metastases <5 cm in diameter, lung metastases <2 cm in diameter, AFP < 1,000 ng ml -1 and HCG <10,000 ng ml -1. The study compared BEP with EP and CR rates were 95.5% and 95.2% respectively. There was no difference in continuous disease free survival (94% and 92%). Those treated without bleomycin did not suffer lung toxicity or significant skin toxicity and, rather more surprisingly, BEP was more myelosuppressive than EP. A trial from the Australian Germ Cell Neoplasm Trial Group has compared PVB with PV in 104 patients with a 'good prognosis' metastatic testicular cancer (Levi et al., 1986) . No significant difference in response was found. The MSKCC compared VAB-6 alternating with EP to a non-randomised control group treated with VAB-6 alone and found no advantage with the alternating schedule (Bosl et al., 1988) .
Much of the toxicity of cisplatin can be avoided by use of the recently developed analogue carboplatin (Calvert et al., 1985) . At conventional dosage carboplatin does not cause significant renal toxicity, neuro-toxicity or oto-toxicity and gastro-intestinal side effects are less severe. The drug is predominantly excreted by the kidneys and myelosuppression is related to glomerular filtration rate as well as dose (Calvert et al., 1985) . There is some evidence that appropriate dose adjustment of carboplatin is also required for optimum anti-tumour effect. The Royal Marsden Hospital Testicular Tumour Unit has performed a pilot study of the combination of carboplatin, etoposide and bleomycin (CEB) in metastatic non-seminomatous germ cell tumours. An analysis of the first 47 patients in this study revealed treatment failure in five patients (three with residual malignancy at surgery, and two recurrences). Carboplatin dose was based on a calculation of the dose required to achieve a particular serum concentration x time (AUC) (Calvert et al., 1985) . Since a range of doses of carboplatin was employed in this study a suggestion emerged that inadequate carboplatin dosage predisposed to recurrence since the AUCs in the five unsuccessful treatments were 2.6, 3.4, 3.5, 3.8 and 3.9 mg ml-1 x min compared with a median of 5 mg ml -1 x min in patients successfully treated. The five patients with active tumour after CEB have all been successfully re-treated with further chemotherapy and all patients in this study are currently disease free. A current MRC prospective randomised trial is comparing BEP and CEB chemotherapy in good prognosis patients.
Considerable progress has been made in identifying chemotherapeutic strategies, of reduced toxicity. However, it is important to ensure that there is not an associated compromise of anti-tumour efficacy. Even in good prognosis subgroups the risk to the patient of dying from progressive malignant disease is far higher than the risk of dying from treatment toxicity. RAGHAVAN, D., HARVEY, V. et al. (1986) . Deletion of bleomycin from therapy for good prognosis advanced testicular cancer. Proc. ASCO, 5, 97. 
